
TSE:MFC
This summary was created by AI, based on 28 opinions in the last 12 months.
Manulife Financial (MFC) has garnered mixed reviews from experts, reflecting a range of perspectives on its current standing and future potential. Several analysts highlight the company's strong dividend yield and its robust performance in Asia, suggesting it may be a worthwhile long-term investment, particularly for those seeking income rather than growth. However, concerns regarding earnings fluctuations, market pullbacks, and comparisons with peers like Sun Life Financial indicate that MFC may not be as attractive as other options in the life insurance sector. Many experts recognize the potential for capital appreciation, yet they caution that the stock faces headwinds, especially when considering broader market dynamics and the performance of similar financial institutions. There is a prevailing sentiment that the stock remains a reliable choice, albeit needing careful monitoring amidst potential market corrections.
In a low interest rate environment, it is very difficult for lifecos to make money. Auditors at some point are going to look at the reinvestment rate required, and there is speculation they may actually lower it, meaning the company has to hold more cash on its balance sheet. However, the franchise value is excellent. Great wealth management business. Growing hand over fist in Asia. If they can just overcome the negative sentiment as it pertains to interest rates and maybe start to take a longer term time horizon into 2017-2018, then you can make a case for it.
The difficulty with the lifecos is that the longer it takes for them to normalize interest rates, the tougher it is going to be on them. They have obligations that go 20 years in the future, and have to do an offset. When we go to a more normalized yield curve, that is a bonus to the lifecos. He is starting to lose patience, and might put this one on the boat if rates don’t improve.
A well-run company and well diversified in Canada and the US, as well as Asia. The issue for all insurance companies right now is the very low interest rate. Thinks interest rates will gradually move up over the next few years and their operation will get better. Long-term it is still a good buy, but shorter term you are probably not going to see a lot of upside.
Share price has been disappointing for the last 1-1.5 years. They’ve had headwinds with the energy sector and their bond and loan portfolios. Resolved their problems from the financial crisis and are on mode now to invest and to grow. Hopefully the macro headwinds are now largely behind them. Stock was punished because they missed expectations, so valuations are now quite attractive at about 1X BV. Likes their exposure to the Asian market. She would start buying here on a pullback.
This has frustrated many, many people for the better part of 10 years. They disappointed in the latest quarter with some of their numbers, and they keep writing down assets. They had quite a bit of exposure to oil/gas which hurt them. It is probably going to sit in the $17-$19 range. He is not interested in it.
It has been difficult for them to get a lot of respect lately. They recently got hit with some problems in the long-term care business in the US. There may be some actuarial revaluations going on in the 3rd quarter, so there could be a possible hit in terms of a write down. However, we have a company that is one of the best capitalized in the industry. Any more they don’t just depend on interest margins to earn their money. Expanding very rapidly and making progress in Asia. Dividend yield of 4.24%.